Objectives Adenosine concentration significantly increases in tumour microenvironment contributing to tumorigenic processes including cell proliferation, survival, invasion and of special interest in this review angiogenesis. Key findings This review summarizes the role of pharmacological adenosine receptor agonist and antagonist in regulating angiogenesis for a better understanding and hence a better management of angiogenesis-associated disorders. Summary Depending upon the pharmacological characteristics of adenosine receptor subtypes, adenosine elicits anti-or pro-angiogenic responses in stimulated cells. Inhibition of the stimulatory effect of adenosine signalling on angiogenesis using specific pharmacological adenosine receptor agonist, and antagonist is a potentially novel strategy to suppress angiogenesis in tumours.
Introduction
Adenosine is an endogenous purine nucleoside consisting of adenine attached to a ribose sugar molecule. [1] This ubiquitous molecule is synthesized at both intracellular and extracellular environments. [2] Within cells, adenosine is formed by breakdown of adenosine monophosphate (AMP) through 5 0 -nucleotidase activity. Furthermore, it can be derived from S-adenosyl homocysteine (SAH) due to the activity of SAH hydrolase. [3] .At extracellular environment, adenosine is widely generated through degradation of adenine nucleotide particularly adenosine tri/ diphosphate (ATP/ADP). Conversion of ATP to adenosine is mediated by two enzymes including ectonucleotide triphosphate diphosphohydrolase 1 (CD39) converting ATP to AMP, followed by dephosphorylation of AMP to adenosine by ecto-5 0 -nucleotidase (CD73). [4] Adenosine is a multifunctional molecule participating actively in different systems including cardiovascular, respiratory, renal functions, and in inflammatory and immune responses. [5, 6] Regulatory effects of adenosine on these systems is mediated through the activation of four distinct extracellular G protein-coupled adenosine receptors (ARs) named A1, A2a, A2b and A3. [7, 8] Each subtype initiates specific intracellular signalling pathways according to differential coupling to intracellular G proteins. [9] Angiogenesis is described as the process of new blood vessels formation from pre-existing vascular network, which includes endothelial cell activation, proliferation and chemotactic-driven migration. [10] Angiogenesis plays a crucial role in many physiological conditions including wound healing and embryogenesis as well as pathological processes such as tumour growth and metastasis. [11, 12] In healthy tissues, angiogenesis is tightly regulated by both pro-angiogenic molecules including vascular endothelial growth factor (VEGF), angiopoietin (ANGPT)-1, platelet-derived growth factor (PDGF) and anti-angiogenic molecules including angiostatin and endostatin. [13, 14] This review summarizes the current knowledge on the role of adenosine and its receptors in angiogenesis process for a better understanding and hence a better management of angiogenesisassociated diseases.
Adenosine signalling pathways
Extracellular adenosine exerts its biological effects through four ARs with distinct expression profiles, pharmacological characteristics and associated signalling pathways. [15] It is known that A1 and A3 ARs are coupled to Gi/o proteins. Hence, activation of A1 and A3 ARs inhibits adenylyl cyclase activity, cyclic-AMP (cAMP) production and subsequent protein kinase A (PKA) activity. [16] In contrast, A2a and A2b ARs are coupled to Gs proteins. Activation of A2 subtypes, A2a and A2b, stimulate adenylyl cyclase activity and enhance cAMP concentration followed by sharp increase in PKA activity. [17] Moreover, A2b ARs are coupled to Gq/11 protein leading to escalation in inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DG) production [18] in stimulated cells. Here, we summarize role of ARs in angiogenesis, however, for detailed information about the general principles of signalling functions of ARs, and readers are referred to the review of Sheth et al. [19] Role of adenosine in angiogenesis Adenosine is a key regulator of angiogenesis. Treating zebrafish embryos with an adenosine analogue NECA (50-N-ethylcarboxamidoadenosine) for 72 h increases blood vessel formation compared with control embryos. [20, 21] Similarly, it has been shown that NECA enhances angiogenesis and neovascularization in transplanted human ovarian tissue in comparison with control group. [22] Moreover, Koszalka et al. [23] showed that CCPA, CGS-21680 and IB-MECA, specific agonists of A1, A2 and A3 ARs, respectively, significantly inhibited B16F10 melanoma growth in CD73 knockout mice in early stage. However after 14 days, all agonists increased angiogenesis in B16F10 melanoma mainly through increasing expression of pro-angiogenic factors. Consistently, Wang et al. [24] showed that adenosine enhances cell growth and induces tube formation in human umbilical vein endothelial cells (HUVECs). Moreover, chronic elevation in adenosine concentration potently increases angiogenesis by upregulating the expression of CXCL1, mouse functional homologue of human IL-8, in the lung of adenosine deaminase-deficient mice. Further studies showed that adenosine deaminase replacement enzyme therapy abrogates adenosine-induced pulmonary angiogenesis in these mice, supporting the role of adenosine in angiogenesis. [25] Agonist/antagonists of A2 adenosine receptor subtypes, A2a and A2b, in angiogenesis
There are studies investigating the pro-angiogenic functions of adenosine under hypoxic conditions. In line with this, Ryzhov et al. [26] showed that under hypoxic conditions and in the presence of adenosine deaminase, only VEGF is overexpressed; however, in the presence of NECA, the secretion of both VEGF and IL-8 is stimulated in human mammary epithelial cells (HMEC-1). Moreover, co-administration of AR antagonists with NECA inhibits VEGF expression and leads to 46% reduction in neovascularization in a mouse ischaemic hindlimb model. In another study, it was shown that hypoxia differentially regulates the expression of AR on endothelial cells. Hypoxia decreases A2a AR mRNA from 1.56 AE 0.3% to 0.16 AE 0.01% of beta-actin expression while it upregulates A2b AR mRNA from 0.08 AE 0.01% to 0.27 AE 0.05% in HUVECs. Consistently, NECA could increase angiogenic factors in hypoxic HUVECs or bronchial smooth muscle cells (BSMCs). Moreover, CVT-6694, a selective A2b AR antagonist, inhibits NECA-induced pro-angiogenic properties. [27] Furthermore, it has been shown that A2a AR has proangiogenic properties and increases tube formation in human lung endothelial cells. This angiogenic function of A2a AR is regulated by hypoxia and hypoxia-inducible factor 2alpha (HIF-2a). [28] To further investigate the role of A2a AR in angiogenesis, Liu et al. [29] showed that inactivation of A2a AR attenuates only oxygen-induced retinopathy angiogenesis not normal retinal vascularization by inhibiting hypoxia-induced retinal VEGF overexpression, supporting the therapeutic potency of A2a AR antagonists for retinopathy of prematurity.
Consistent with the regulatory role of A2 ARs subtypes, A2a and A2b, on angiogenesis, Emens et al. [30] demonstrated that adenosine-induced A2 subtypes activation elicit pro-angiogenic signalling functions by increasing production of thrombospondin-1 (TSP-1), a matricellular protein and activation of cAMP/PKA pathway in macrophages (Figure 1) . Consistently, they found that treatment of macrophages with either PKA inhibitor or anti-TSP-1 antibody abrogates adenosine-induced vascularization and angiogenesis, supporting the role of these molecules in the pro-angiogenic effects of adenosine. In contrast with these findings, Desai et al. [31] showed that activation of A2a AR stimulates angiogenesis by suppression of TSP-1 secretion. They also reported that A2a AR agonists including CGS-21680 or MRE0094 decrease TSP-1 protein secretion and stimulate vascular tube formation in a dose-dependent manner, which is totally abrogated in the presence of ZM241385, A2a AR antagonist.
To further support the regulatory role of A2a AR in angiogenesis, Montesinos et al. [32] showed that CGS-21680, a selective A2a AR agonist, significantly enhances angiogenesis and wound repair only in wild-type not in A2a AR knockout mice. Consistent with these findings, administration of CGS-21680, an A2a AR agonist, increases neovascularization in three-day-old wounds, while has no effect on six-day-old counterparts, suggesting that A2a AR promotes neovascularization and angiogenesis merely in the early stages of wound repair in mice. [33] Moreover, A2a AR activation induces the phenotypic switch of macrophages into the angiogenic 'M2-like' phenotype and increases expression of VEGF, IL-10 and nitric oxide synthase (iNOS) in macrophages. [34, 35] To further investigate the regulatory role of the A2a AR in angiogenesis, Pinhal-Enfield et al. [36] showed that agonists of Toll-like receptors 2, 4, 7, 9 upregulate VEGF production only in the presence of A2a but not A1 AR agonists.
There are several studies supporting the pivotal role of A2b ARs on angiogenesis by increasing expression levels of angiogenic factors including VEGF, IL-8, in microvascular endothelial cells. [37] In line with this, it has been shown that only IPDX, an A2b AR antagonist, not SCH58261 or MRS1191, the selective A2a and A3 AR antagonists, respectively, inhibits overexpression of VEGF and IL-8 in stimulated cells. [37] Consistently, administration of a selective A2b AR agonist, Bay60-6583, increases VEGF-A expression by activating signal transducer and activator of transcription 3 (STAT3) pathway, whereas administration of PSB1115, an inhibitor of A2b AR, downregulates VEGF-A expression in melanoma mice model. [38] Furthermore, A2b AR also regulates expression of other angiogenic factors including endothelial nitric oxide synthase (eNOS) in endothelial cells. In line with this, Du et al. [39] showed that NECA-induced A2b AR activation increases VEGF and eNOS expression by activating cAMP-PKA-CREB and PI3K/AKT signalling pathways, respectively, in human microvascular endothelial cells. Inhibition of A2b AR using either A2b AR antagonist, MRS1754 or A2b AR gene silencing suppressed NECA-induced VEGF and eNOS overexpression, supporting the critical role of A2b AR in NECA-induced angiogenesis. Similarly, Rizvi et al. [40] showed that stimulatory effect of NECA on angiogenesis is inhibited in the presence of MRS-1706, a selective A2b AR antagonist in zebrafish embryos. These results clearly support the stimulatory effect of A2a and A2b ARs in angiogenesis, supporting the therapeutic potency of A2 AR subtype antagonists in suppressing angiogenesis in angiogenesis-associated disorders. 
Conclusion
Adenosine as an omnipresent metabolite is involved in different processes, and any dysregulation in the generation of this molecule could contribute to the pathogenesis of certain diseases from cancer [2, 41] to inflammatory disorders. [42, 43] Recently, adenosine and its receptors attracted tremendous attention in cancer pathology and provide new research area in therapy purposes. Increased level of adenosine in tumour microenvironment regulates tumour growth by modulating tumorigenic processes including angiogenesis. There are studies showing that adenosine analogues [44] and ARs potently modulate angiogenesis, supporting the clinical significance of these molecules in cancer treatment.
The signalling function of adenosine on angiogenesis is diverse and depends upon AR subtypes (Figure 1 ). Signalling of A1 and A2a and A2b ARs is mostly pro-angiogenic. Regarding the pro-angiogenic effect of A1AR, Clark et al. [45] showed that activation of A1 AR with CPA, an A1 AR selective agonist, increased blood vessel number up to 40% in chicken chorioallantoic membrane (CAM) model, which was abrogated in the presence of WRC-0571, an A1 AR antagonist. They also found that CPA-induced release of VEGF from mononuclear cells and CPA-pretreated medium of human mononuclear cells stimulated capillary formation by 48%, supporting the stimulatory effect of A1 AR on angiogenesis. However, signalling of A3 AR is complex and in some cases contradictory. For instance, activation of A3 AR by a selective agonist, IB-MECA, increases expression of angiogenic factors including angiopoietin 2 in melanoma and human mast cell line, HMC-1. [46] Similarly, Gessi et al. [47] showed that Cl-IB-MECA, an A3 AR agonist, increases expression of HIF-1a and VEGF in different cell types including human colon carcinoma cells, human melanoma cells and glioblastoma cell lines, which is abrogated in the presence of A3 AR antagonist, MRE3008F20. [48, 49] In contrast with these findings, it has been shown that downregulation of the A3 AR enhances expression of pro-angiogenic mediators including VEGF and IL-8 in human mast cells. [50] Similarly, using thio-Cl-IB-MECA, a novel A3 AR agonist, suppresses migration and tube formation by regulating PI3K/AKT/mTOR and ERK signalling in endothelial cells. [51] These studies clearly support the complexity of adenosine signalling on angiogenesis. It is recommended that further investigation be performed in this regard to determine the molecular mechanism and the exact role of each AR signalling in angiogenesis. The information gained from all these studies helps to design novel selective AR agonists or antagonists and has great clinical significance in terms of the treatment of angiogenesis-associated disorders including malignant tumours.
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